Denali Therapeutics (NASDAQ:DNLI) Price Target Lowered to $22.00 at Stifel Nicolaus

Denali Therapeutics (NASDAQ:DNLI) had its price objective dropped by analysts at Stifel Nicolaus from $26.00 to $22.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a “hold” rating on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 13.99% from the company’s current price.

Other research analysts also recently issued research reports about the company. The Goldman Sachs Group reduced their target price on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, February 29th. HC Wainwright dropped their price target on Denali Therapeutics from $105.00 to $95.00 and set a “buy” rating on the stock in a research report on Wednesday, February 28th. UBS Group dropped their price target on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, April 9th. Finally, Wedbush reissued an “outperform” rating and issued a $31.00 price target on shares of Denali Therapeutics in a research report on Wednesday, February 28th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.33.

Denali Therapeutics Stock Up 14.5 %

Shares of NASDAQ DNLI traded up $2.45 during midday trading on Wednesday, reaching $19.30. The company had a trading volume of 492,491 shares, compared to its average volume of 1,153,974. Denali Therapeutics has a one year low of $14.56 and a one year high of $33.31. The firm’s fifty day moving average price is $18.82 and its 200-day moving average price is $18.84. The stock has a market cap of $2.75 billion, a PE ratio of -17.87 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same quarter in the prior year, the firm posted ($0.80) EPS. As a group, equities research analysts expect that Denali Therapeutics will post -2.61 EPS for the current year.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $18.29, for a total value of $30,471.14. Following the completion of the transaction, the director now owns 118,043 shares of the company’s stock, valued at $2,159,006.47. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, Director Steve E. Krognes sold 92,500 shares of Denali Therapeutics stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $20.50, for a total value of $1,896,250.00. Following the sale, the director now owns 47,341 shares in the company, valued at $970,490.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $18.29, for a total transaction of $30,471.14. Following the completion of the transaction, the director now directly owns 118,043 shares in the company, valued at $2,159,006.47. The disclosure for this sale can be found here. Insiders sold 110,955 shares of company stock valued at $2,218,802 over the last 90 days. Insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in DNLI. Wellington Management Group LLP boosted its stake in Denali Therapeutics by 3.6% during the 3rd quarter. Wellington Management Group LLP now owns 7,288,960 shares of the company’s stock worth $150,371,000 after purchasing an additional 250,784 shares during the period. Gotham Asset Management LLC purchased a new position in Denali Therapeutics during the 3rd quarter valued at about $400,000. Eventide Asset Management LLC increased its holdings in Denali Therapeutics by 98.4% during the 3rd quarter. Eventide Asset Management LLC now owns 621,850 shares of the company’s stock valued at $12,829,000 after acquiring an additional 308,443 shares in the last quarter. abrdn plc purchased a new stake in shares of Denali Therapeutics during the fourth quarter worth about $6,971,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Denali Therapeutics in the third quarter worth approximately $772,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.